Serum Concentration of lgG in Patient With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- Diagnostic Test: Quantitative measurements the changes of IgG glycosylation
- Registration Number
- NCT03394092
- Lead Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Brief Summary
The aim of this study is to investigate the changes in glycopeptides of serum immunoglobulin G in patients with acute myocardial infarction and the relationships between its change and prognosis.
- Detailed Description
Immunoglobin G (IgG), a highly abundant glycoprotein in serum, is known to participate in blood immune responses.It has been an increasing interest in the analysis of the abnormal glycosylation of human lgG in healthy and disease states, such as autoimmune diseases and cancer.However, there is few relevant studies about the changes in glycopeptides of serum immunoglobulin G in patients with acute myocardial infarction. This study was performed for the frst timeto assess the quantitative changes of serum IgG glycosylation in patients with acute myocardial infarction and the relationships between its change and prognosis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- diagnosed as STEMI.
- with left ventricular ejection fraction（LVEF）>=45%
- written informed consents are obtained
- admitted within 24 hours after chest pain attacked
-
complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy
- complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
- with acute or chronic infection, surgery or trauma in the last month
- secondary hypertension, severe liver dysfunction,severe renal insufficiency
- with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Control Quantitative measurements the changes of IgG glycosylation 50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission. STEMI Quantitative measurements the changes of IgG glycosylation The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
- Primary Outcome Measures
Name Time Method Serum quantitative determination of lgG 12 months Quantitative measurements the changes of serum IgG glycosylation by HPLC-MRM
- Secondary Outcome Measures
Name Time Method MACEs during 12-month follow-up 12 months Association of quantitative level of lgG with prognosis
The changes of LVEF in two groups 12 months Association of quantitative level of lgG with the changes of cardiac function
Relationship between the serum hs-CRP and the quantitative level of lgG glycopeptides in peripheral blood. 12 months correlation between the serum hs-CRP and lgG
Trial Locations
- Locations (1)
The First Affiliated Hospital of Dalian Medical University
🇨🇳Dalian, China